PE20010027A1 - Uso de interferon alfa pegilado en pacientes con melanoma - Google Patents
Uso de interferon alfa pegilado en pacientes con melanomaInfo
- Publication number
- PE20010027A1 PE20010027A1 PE2000000310A PE0003102000A PE20010027A1 PE 20010027 A1 PE20010027 A1 PE 20010027A1 PE 2000000310 A PE2000000310 A PE 2000000310A PE 0003102000 A PE0003102000 A PE 0003102000A PE 20010027 A1 PE20010027 A1 PE 20010027A1
- Authority
- PE
- Peru
- Prior art keywords
- melanoma
- sticked
- patients
- alpha interferon
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE AL USO DE INTERFERON ALFA 2a O 2b PEGILADO UTIL PARA EL TRATAMIENTO DE MELANOMA (MELANOMA CUTANEO) EN UN PACIENTE CON MELANOMA QUE HA SIDO QUIRURGICAMENTE REMOVIDO; O EN UN PACIENTE NUEVO; O A UN PACIENTE AL QUE SE LE HA DIAGNOSTICADO RECIENTEMENTE MELANOMA; O HA EXPERIMENTADO TRATAMIENTO O ES INTOLERANTE O RESISTENTE AL INTERFERON ALFA; UTILIZANDOSE 3µg/Kg A 9 µg/Kg UNA VEZ POR SEMANA POR UN PERIODO DE POR LO MENOS 24 MESES; PARA INCREMENTAR EL TIEMPO DE SUPERVIVENCIA LIBRE DE PROGRESION
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28836699A | 1999-04-08 | 1999-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20010027A1 true PE20010027A1 (es) | 2001-02-05 |
Family
ID=23106795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2000000310A PE20010027A1 (es) | 1999-04-08 | 2000-04-06 | Uso de interferon alfa pegilado en pacientes con melanoma |
Country Status (22)
Country | Link |
---|---|
EP (3) | EP1535622B1 (es) |
JP (1) | JP2000319195A (es) |
CN (1) | CN1390132A (es) |
AR (1) | AR023398A1 (es) |
AT (3) | ATE496631T1 (es) |
AU (1) | AU771569B2 (es) |
BR (1) | BR0009646A (es) |
CA (1) | CA2303992A1 (es) |
CO (1) | CO5170404A1 (es) |
CY (1) | CY1108922T1 (es) |
DE (3) | DE60045591D1 (es) |
DK (2) | DK1535622T3 (es) |
ES (2) | ES2319776T3 (es) |
HK (2) | HK1032349A1 (es) |
HU (1) | HU230057B1 (es) |
MY (1) | MY126763A (es) |
NO (1) | NO328111B1 (es) |
PE (1) | PE20010027A1 (es) |
PT (2) | PT1535622E (es) |
TW (1) | TWI292320B (es) |
WO (1) | WO2000061175A2 (es) |
ZA (1) | ZA200108173B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140038382A (ko) | 2011-03-10 | 2014-03-28 | 프로벡투스 파마슈티컬스 인코포레이티드 | 암의 치료 증대를 위한 국소 면역조절 치료제와 전신 면역조절 치료제의 복합제 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4492537A (en) | 1982-12-10 | 1985-01-08 | Awerkamp John B | Fluid-operated oil or water well pump |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
KR960705579A (ko) | 1993-11-10 | 1996-11-08 | 에릭에스. 딕커 | 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates) |
US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
-
2000
- 2000-04-06 TW TW089106309A patent/TWI292320B/zh not_active IP Right Cessation
- 2000-04-06 CO CO00025236A patent/CO5170404A1/es not_active Application Discontinuation
- 2000-04-06 AT AT08020311T patent/ATE496631T1/de not_active IP Right Cessation
- 2000-04-06 AR ARP000101574A patent/AR023398A1/es unknown
- 2000-04-06 ES ES05002951T patent/ES2319776T3/es not_active Expired - Lifetime
- 2000-04-06 PT PT05002951T patent/PT1535622E/pt unknown
- 2000-04-06 BR BR0009646-6A patent/BR0009646A/pt not_active Application Discontinuation
- 2000-04-06 EP EP05002951A patent/EP1535622B1/en not_active Expired - Lifetime
- 2000-04-06 HU HU0200775A patent/HU230057B1/hu not_active IP Right Cessation
- 2000-04-06 EP EP00107101A patent/EP1043026B1/en not_active Expired - Lifetime
- 2000-04-06 PT PT00107101T patent/PT1043026E/pt unknown
- 2000-04-06 CA CA002303992A patent/CA2303992A1/en not_active Abandoned
- 2000-04-06 DK DK05002951T patent/DK1535622T3/da active
- 2000-04-06 DE DE60045591T patent/DE60045591D1/de not_active Expired - Lifetime
- 2000-04-06 AU AU42046/00A patent/AU771569B2/en not_active Ceased
- 2000-04-06 AT AT00107101T patent/ATE296639T1/de active
- 2000-04-06 PE PE2000000310A patent/PE20010027A1/es not_active Application Discontinuation
- 2000-04-06 WO PCT/US2000/009129 patent/WO2000061175A2/en active Application Filing
- 2000-04-06 DK DK00107101T patent/DK1043026T3/da active
- 2000-04-06 DE DE60041290T patent/DE60041290D1/de not_active Expired - Lifetime
- 2000-04-06 EP EP08020311A patent/EP2025344B1/en not_active Expired - Lifetime
- 2000-04-06 DE DE60020444T patent/DE60020444T2/de not_active Expired - Lifetime
- 2000-04-06 ES ES00107101T patent/ES2239954T3/es not_active Expired - Lifetime
- 2000-04-06 AT AT05002951T patent/ATE419001T1/de active
- 2000-04-06 JP JP2000105524A patent/JP2000319195A/ja not_active Withdrawn
- 2000-04-06 CN CN00808452A patent/CN1390132A/zh active Pending
- 2000-04-07 MY MYPI20001454A patent/MY126763A/en unknown
-
2001
- 2001-03-26 HK HK01102202A patent/HK1032349A1/xx not_active IP Right Cessation
- 2001-10-04 ZA ZA200108173A patent/ZA200108173B/en unknown
- 2001-10-05 NO NO20014852A patent/NO328111B1/no not_active IP Right Cessation
-
2005
- 2005-11-02 HK HK05109748.1A patent/HK1075416A1/xx not_active IP Right Cessation
-
2009
- 2009-03-24 CY CY20091100351T patent/CY1108922T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY144318A (en) | Methods of treating hiv infection. | |
MXPA02000282A (es) | Composiciones de cuidado personal. | |
ES2172288T3 (es) | Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c. | |
ATE300306T1 (de) | Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung | |
PE20001109A1 (es) | Derivados de rivabirina | |
CL2008003938A1 (es) | Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00). | |
PE20001369A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa pegilado | |
HK1056681A1 (en) | Gabapentin analogues for sleep disorders | |
SE9400935D0 (sv) | Tandarrangemang | |
ZA941525B (en) | Use of riluzole in the treatment of nero-AIDS | |
HK1060067A1 (en) | Compositions for antitumour treatment containing ecteinascidin 743 | |
IL115589A0 (en) | Use of cck-b antagonists in pharmaceutical compositions | |
PE20010027A1 (es) | Uso de interferon alfa pegilado en pacientes con melanoma | |
BRPI0608326A2 (pt) | suporte de exoesqueleto para colocação de uma fita de tratamento dental | |
BR9911005A (pt) | Uso de ozÈnio para a preparação de medicamentos para o tratamento de cáries dentárias | |
ES2108122T3 (es) | Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas. | |
PE20010026A1 (es) | Composicion que comprende interferon alfa pegilado | |
BG103859A (en) | The use of 1-ar(alk)yl-imidazolin-2-on for the treatment of fear and stress conditions | |
PE20010226A1 (es) | Uso de interferon modificado con peg para la preparacion de un medicamento para el tratamiento de leucemia mielocitica cronica | |
AR013424A1 (es) | Uso de uridina para la preparacion de una composicion farmaceutica util para inhibir la toxicidad de los analogos de pirimidina | |
FR2669821B1 (es) | ||
HUP0302371A2 (hu) | Béta-blokkolót és adott esetben koleszterinszint-csökkentőt tartalmazó új gyógyszerkészítmény | |
MXPA04002098A (es) | El uso de estrogenos no afeminantes como agentes retinoprotectores para el tratamiento del glaucoma. | |
HU9500708D0 (en) | Optically active alkylammonium(amino-3phenyl)-1ethanesulfonate derivatives, preparation and use thereof | |
HU9500709D0 (en) | Optically active hydroquinine (amino-3-phenyl)-1-ethanesulfonate, preparation and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |